Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
8.38
+0.10 (1.21%)
At close: Mar 31, 2025, 4:00 PM
8.39
+0.01 (0.16%)
After-hours: Mar 31, 2025, 5:43 PM EDT
Amneal Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 2,794 | 2,394 | 2,212 | 2,094 | 1,993 | Upgrade
|
| Revenue Growth (YoY) | 16.73% | 8.20% | 5.67% | 5.08% | 22.51% | Upgrade
|
| Cost of Revenue | 1,778 | 1,530 | 1,421 | 1,310 | 1,340 | Upgrade
|
| Gross Profit | 1,016 | 863.87 | 791.46 | 783.95 | 652.32 | Upgrade
|
| Selling, General & Admin | 476.44 | 429.68 | 399.7 | 365.5 | 326.73 | Upgrade
|
| Research & Development | 190.71 | 163.95 | 195.69 | 201.85 | 179.93 | Upgrade
|
| Other Operating Expenses | - | -1.14 | -3.96 | - | - | Upgrade
|
| Operating Expenses | 667.15 | 592.49 | 591.43 | 567.35 | 506.66 | Upgrade
|
| Operating Income | 348.36 | 271.38 | 200.03 | 216.6 | 145.66 | Upgrade
|
| Interest Expense | -258.6 | -210.63 | -158.38 | -136.33 | -146 | Upgrade
|
| Currency Exchange Gain (Loss) | -6.85 | 1.67 | -12.36 | -0.36 | 16.35 | Upgrade
|
| Other Non Operating Income (Expenses) | -42.66 | 5.12 | 17.83 | 15.33 | 2.59 | Upgrade
|
| EBT Excluding Unusual Items | 40.26 | 67.54 | 47.13 | 95.25 | 18.6 | Upgrade
|
| Merger & Restructuring Charges | -2.36 | -1.75 | -2.13 | -9.91 | -11.39 | Upgrade
|
| Gain (Loss) on Sale of Assets | 3.76 | - | - | - | 0.12 | Upgrade
|
| Asset Writedown | -0.92 | -36.13 | -11.11 | -22.69 | -34.58 | Upgrade
|
| Legal Settlements | -96.69 | -1.82 | -269.93 | -25 | -5.86 | Upgrade
|
| Other Unusual Items | 0.93 | -37.31 | -1.02 | -10.57 | - | Upgrade
|
| Pretax Income | -55.01 | -40.27 | -248.13 | 31.37 | -35.78 | Upgrade
|
| Income Tax Expense | 18.86 | 8.45 | 6.66 | 11.2 | -104.36 | Upgrade
|
| Earnings From Continuing Operations | -73.88 | -48.72 | -254.79 | 20.17 | 68.58 | Upgrade
|
| Minority Interest in Earnings | -43.01 | -35.27 | 124.8 | -9.55 | 22.48 | Upgrade
|
| Net Income | -116.89 | -83.99 | -129.99 | 10.62 | 91.06 | Upgrade
|
| Net Income to Common | -116.89 | -83.99 | -129.99 | 10.62 | 91.06 | Upgrade
|
| Net Income Growth | - | - | - | -88.33% | - | Upgrade
|
| Shares Outstanding (Basic) | 309 | 176 | 151 | 149 | 147 | Upgrade
|
| Shares Outstanding (Diluted) | 309 | 176 | 151 | 152 | 149 | Upgrade
|
| Shares Change (YoY) | 75.42% | 16.69% | -0.58% | 1.95% | 12.72% | Upgrade
|
| EPS (Basic) | -0.38 | -0.48 | -0.86 | 0.07 | 0.62 | Upgrade
|
| EPS (Diluted) | -0.38 | -0.48 | -0.86 | 0.07 | 0.61 | Upgrade
|
| EPS Growth | - | - | - | -88.52% | - | Upgrade
|
| Free Cash Flow | 234.76 | 298.78 | 16.3 | 190.88 | 317.17 | Upgrade
|
| Free Cash Flow Per Share | 0.76 | 1.70 | 0.11 | 1.26 | 2.13 | Upgrade
|
| Gross Margin | 36.35% | 36.09% | 35.77% | 37.44% | 32.74% | Upgrade
|
| Operating Margin | 12.47% | 11.34% | 9.04% | 10.35% | 7.31% | Upgrade
|
| Profit Margin | -4.18% | -3.51% | -5.88% | 0.51% | 4.57% | Upgrade
|
| Free Cash Flow Margin | 8.40% | 12.48% | 0.74% | 9.12% | 15.92% | Upgrade
|
| EBITDA | 584.55 | 500.78 | 440.21 | 450 | 381.05 | Upgrade
|
| EBITDA Margin | 20.92% | 20.92% | 19.90% | 21.49% | 19.12% | Upgrade
|
| D&A For EBITDA | 236.19 | 229.4 | 240.18 | 233.41 | 235.39 | Upgrade
|
| EBIT | 348.36 | 271.38 | 200.03 | 216.6 | 145.66 | Upgrade
|
| EBIT Margin | 12.47% | 11.34% | 9.04% | 10.35% | 7.31% | Upgrade
|
| Effective Tax Rate | - | - | - | 35.70% | - | Upgrade
|
Updated Feb 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.